Peter Feinstein co-founded BioVentures Investors with Marc Goldberg, forming its first fund in 1998.
Prior to the closing of Fund I, he served as Chairman and CEO of Feinstein Kean Healthcare (FKH), a communications and strategic consulting firm which he founded in 1987. Under his leadership, FKH grew from a start-up to the dominant communications and investor relations firm in the biotechnology industry. Following the 1999 acquisition of FKH by WPP plc, Peter assumed full-time status with BioVentures Investors.
Peter entered the biotechnology industry in December 1981 as a consultant to Biogen. In 1983, following the Biogen IPO, he was hired by Dr. Gilbert to serve as Vice-President, Corporate Communications, at Biogen, where his responsibilities included global investor relations for this leading international biotechnology company.
Peter was a co-founder with Marc of the Massachusetts Biotechnology Council, serving as Executive Director and was a Director for 12 years. He has also served on the Executive Committee of the Board of Associates of the Whitehead Institute for Biomedical Research, where he co-chaired the Whitehead Circle, and on the Executive Board of the Health Science and Technology Division of Harvard and MIT. As a BVI partner, he has served on the boards of Hospital Care Online (Chm), Sciona (interim CEO), Rcadia Medical Imaging (Chm), Rachiotek (Chm), Cylene Pharmaceuticals, HydroCision, sGC Pharma, BioValve, ActivBiotics, Pintex, CombinatoRx (obs) and Therion (obs).
Peter received his B.A. from New York University.
Peter Feinstein General Partner